IM Cannabis Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMCC research report →
Price Chart
About the company
IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods throughout international markets such as Israel, Germany, and Canada. The company offers a range of cannabis products, including flowers and specifically formulated cannabis extracts, marketed under its IMC brand.
- CEO
- Oren Shuster
- IPO
- 2020
- Employees
- 44
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on IMCC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $823.58K
- P/E
- -0.02
- PEG
- 0.00
- P/S
- 0.04
- P/B
- -0.17
- EV/EBITDA
- -1.01
- Div Yield
- 0.00%
- Gross Margin
- 10.11%
- Op Margin
- -32.93%
- Net Margin
- -65.57%
- ROE
- 528.80%
- ROIC
- -173.85%
Latest fiscal year · YoY change
- Revenue
- $54.73M+1.3%
- Gross Profit
- $9.69M+14.6%
- Op Income
- $-11,587,000
- Net Income
- $-11,319,000-6.9%
- EPS
- $-80.10+40.8%
- OCF Growth
- +537.9%
- FCF Growth
- +481.4%
- 52W High
- $187.20
- 52W Low
- $0.36
- 50D MA
- $4.41
- 200D MA
- $22.57
- Beta
- 2.21
- RSI (14)
- 30
- Avg Volume
- 915.52K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IM Cannabis turned profitable in Q1 2025, driven by strong Germany growth, major margin improvement, and sharp expense reduction despite weakness in Israel.· May 15, 2025
- Q1 2025 revenue was $12.5 million, up 4% year over year, with Germany offsetting a $6.1 million revenue decline in Israel.
- Gross profit rose to $3.4 million from $1.8 million, and gross margin improved 87% versus Q1 2024.
- Adjusted EBITDA improved to a $0.6 million profit from a $2.2 million loss, and net profit was about $0.2 million.
- Germany revenue increased 569% year over year and represented 62% of total revenue in the quarter.
- Operating expenses fell 56% year over year to $3.3 million, reflecting the company’s cost-cutting and integration efforts.
Q1 2025 revenue was $12.5 million, compared with $12.1 million in Q1 2024, up $0.4 million or 4%. Gross profit was $3.4 million versus $1.8 million a year ago, up $1.6 million or 94%, while cost of revenue declined to $9.1 million from $10.3 million. Adjusted EBITDA was a profit of $0.6 million versus a loss of $2.2 million in Q1 2024; the company also reported net profit of about $0.2 million and diluted income per share of $0.09 versus a loss of $2.52 per share. Looking ahead, management did not provide formal next-quarter or full-year financial guidance; it said the company plans to fund operations from existing and future working capital, available credit facilities, and potentially additional capital or financing as needed.
Oren Shuster framed Q1 as proof that the company’s two-year restructuring and integration work is starting to show up in the numbers. He emphasized execution, shifting resources to the highest-ROI opportunities, and leaning into the integrated supply chain, especially in Germany where the company launched 12 new strains and generated about EUR 3 million, or 39% of FLOWR sales in Germany. He also said the company reached its goal of being positive at the group level and is now focused on continuing to execute its strategy.
Uri Birenberg highlighted that adjusted EBITDA improved by almost $3 million year over year to a $0.6 million profit, and net profit reached approximately $0.2 million. He noted revenue growth in Germany of 569% and a 56% reduction in operating expenses, with G&A at $2 million, selling and marketing at $1.3 million, and total operating expenses at $3.3 million. Cash and cash equivalents were $1.4 million at March 31, 2025, up from $0.9 million at year-end 2024; he said the company expects to finance operations through existing and future working capital, available credit facilities, and additional sources of capital if needed.
The only analyst question focused on why approval of the remaining 25% of Focus ownership mattered at this time. Management said the transaction is tied to regulatory and tax requirements, explaining that holding 100% of Focus helps clear intercompany balances and convert long-term loan amounts into equity without triggering tax issues. They said the process has been underway for some time and that external valuation was used to support the acquisition of the remaining stake.
The call showed a clear turnaround: IM Cannabis reported positive adjusted EBITDA and net profit, with sharp gross margin improvement and a much lower expense base. Management said Germany is scaling rapidly, new strain launches are gaining traction, and the integrated supply chain is delivering visible financial benefits.
The Israeli business weakened materially, with revenue down 56% year over year, and management said that shift in focus plus supply delays hurt that segment. Cash remains relatively limited at $1.4 million, liabilities increased to $41,761, and management did not provide formal financial guidance, only a general statement that it may need additional capital or financing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 28.4%
- Shares Outstanding
- 1.65M
- Float Shares
- 468.13K
of shares held by institutions
12 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 43.63K | ▼ 176.72K |
| Tower Research Capital LLC (Trc) | 149 | ▲ 149 |
| Jpmorgan Chase & Co | 2 | ▲ 2 |
| Ubs Group AG | 1 | ▼ 2 |
Our IMCC coverage
Recent articles, reports, and earnings notes.
No research on IMCC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMCC report →IM Cannabis Corp. Appoints New CEO to Lead Technology-Driven Business Expansion
prnewswire.com · Nov 20
IM Cannabis Announces Intention to Complete 3:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
prnewswire.com · Nov 18
IM Cannabis Corp. Announces Third Quarter 2026 Financial Results
prnewswire.com · Nov 13
IM Cannabis Raises US$1,200,000 of Gross Proceeds in Convertible Note Financing
prnewswire.com · Nov 4
IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet
prnewswire.com · Sep 29
IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares
prnewswire.com · Sep 24
IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement
prnewswire.com · Sep 23
IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares
prnewswire.com · Sep 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.